The side effects of Wegovy: myth, reality, and what the evidence says

The biggest misconception: that Wegovy's side effects are unpredictable or uniformly severe

Ask anyone who has read the patient information leaflet and they will tell you the side-effect list looks alarming. The reality, borne out by the STEP 1 trial published in the New England Journal of Medicine, is more nuanced. In that 68-week study, gastrointestinal events were common but predominantly mild to moderate in severity, and most participants continued treatment. The dose-escalation schedule (starting at 0.25mg and moving upward in roughly four-week steps, guided by the prescriber) exists precisely because the body adapts better when the medicine is introduced gradually. The side effects are real; the idea that they are inevitable at their worst is not.

The other myth worth addressing early is that nausea signals the medicine is working. It does not. It signals the stomach is slowing down as the drug suppresses appetite (a known mechanism of GLP-1 receptor agonists) but severity of nausea has no relationship to how much weight a person loses. Framing nausea as a necessary price to pay is both inaccurate and unhelpful.

A fuller breakdown of Wegovy's side effect profile covers frequency data in more detail for those who want the numbers.

The side effects you are most likely to notice, and when

Nausea sits at the top of the list, followed by diarrhoea, constipation, vomiting, abdominal discomfort, indigestion, burping and fatigue. The NHS medicines page for semaglutide sets these out clearly and is worth reading before starting treatment. Most people find these effects peak in the first few days after a dose increase, then ease within a week or two as the body settles.

A few practical patterns tend to help: eating smaller meals, avoiding very fatty or spicy food, staying well hydrated, and not lying down immediately after eating. None of these replace clinical advice from a prescriber, they are simply what the evidence suggests reduces the burden for most people.

Less common but reported effects include headache, dizziness, tiredness and injection-site reactions (redness or minor bruising where the pen is used). On that point: Wegovy arrives in a pre-filled pen, and for patients ordering through a regulated online pharmacy, the plain, unbranded box shows up via tracked DPD delivery, the same pen described in the leaflet, nothing improvised.

Questions about a specific and less-discussed side effect (hair loss, for instance) come up more than you might expect, and there is a dedicated page on that topic.

When to get medical help: the side effects that need urgent attention

The following symptoms should prompt you to stop Wegovy and seek medical help promptly. They are uncommon, but that does not make them trivial.

Severe, persistent stomach pain (especially pain that radiates to the back, with or without vomiting) can indicate acute pancreatitis. The MHRA's January 2026 Drug Safety Update identified this as a known though infrequent risk across GLP-1 medicines; do not wait to see if it passes. Gallbladder problems (sudden pain in the upper right abdomen, particularly after eating) also require urgent assessment.

If you are trying to understand whether a symptom you are experiencing is a side effect from Wegovy, our dedicated page walks through how to identify and assess what you are noticing. Seek help for signs of a serious allergic reaction: swelling of the face, lips, tongue or throat, difficulty breathing, or a widespread rash. Severe dehydration from prolonged vomiting or diarrhoea is another situation requiring prompt attention, since it can affect kidney function.

If low mood, thoughts of self-harm or any significant mood change develops during treatment, contact a healthcare professional without delay. Patients with a history of diabetic retinopathy should tell their prescriber before starting, as rapid changes in blood glucose control have been associated with temporary worsening. Any suspected side effect can and should be reported to the MHRA via the Yellow Card scheme, patient reports genuinely inform post-market safety surveillance.

The safety considerations for people with cardiovascular conditions are covered separately for those with specific questions in that area.

How a prescriber factors side effects into the decision to treat

Whether Wegovy is appropriate for a given person is never decided on tolerability profile alone. A prescriber considers contraindications (a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, a history of pancreatitis), other medicines being taken, and the individual's weight-related health picture. Pregnancy, breastfeeding, planning to conceive, and being under 18 all mean Wegovy is not recommended; these are not advisory cautions but clear clinical boundaries.

For anyone considering treatment, that clinical conversation is the right starting point. Our prescribers discuss suitability and the full semaglutide side effect picture as part of the free consultation, no algorithm, a real clinician reading your answers the same day. You can start that consultation here if you want a clinical view on whether Wegovy is right for you.

There is also broader context worth reading on weight management treatment options if you are still weighing up the landscape.